ALLO Hedge Fund Ownership (Q1 2026)

Allogene Therapeutics Inc (ALLO)

203 + Investors. Track Smart Money conviction in ALLO. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ALLO

Based on 204 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added ALLO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

204 hedge funds hold ALLO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +20% more funds vs a year ago

fund count last 6Q

+34 new funds entered over the past year (+20% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟢

More buyers than sellers — 69% buying

131 buying58 selling

Last quarter: 131 funds were net buyers (51 opened a brand new position + 80 added to an existing one). Only 58 were sellers (43 trimmed + 15 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+21 vs last Q)

new funds entering per quarter

Funds opening a new ALLO position: 17 → 31 → 30 → 51. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 25% medium ■ 23% new

107 out of 204 hedge funds have held ALLO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +95% but shares only +14% — price-driven

Value

+95%

+14%

Last quarter: the total dollar value of institutional holdings rose +95%, but actual share count only changed +14%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

30 → 17 → 31 → 30 → 51 new funds/Q

New funds entering each quarter: 17 → 31 → 30 → 51. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Veteran-anchored — 61% veterans vs 25% newcomers

■ 61% veterans ■ 13% 1-2yr ■ 25% new

Entry-cohort mix of 210 holders: 129 (61%) are 2+ year veterans, 28 entered 1–2 years ago, and 53 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 42% AUM from top-100 funds

42% from top-100 AUM funds

45 of 204 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in ALLO. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.8

out of 10

Low Exit Risk

Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	203	168	20.83%
13F Shares	186M	163M	14.11%
Total Value	$430M	$221M	95.05%
New Positions	50	30	+20
Increased Positions	77	53	+24
Closed Positions	15	32	-17
Reduced Positions	42	45	-3
Total Calls	4	4	-
Total Puts	2	2	-
PUT/CALL Ratio	0.5	0.5	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

203

168

20.83%

13F Shares

186M

163M

14.11%

Total Value

$430M

$221M

95.05%

New Positions

+20

Increased Positions

+24

Closed Positions

-17

Reduced Positions

-3

Total Calls

Total Puts

PUT/CALL Ratio

0.5

Bullish

Institutional Holders (2026 Q2)

203 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ALLO. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ALLO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Pfizer Inc	27.55%	22,032,040	$46.9M
2	GordonMD Global Investments LP	5.33%	5,298,000	$11.0M
3	Sio Capital Management, LLC	4.59%	13,323,431	$27.7M
4	Wildcat Capital Management, LLC	2.66%	2,920,787	$6.1M
5	Patient Square Capital LP	1.63%	5,050,000	$10.5M
6	Frazier Life Sciences Management, L.P.	1.02%	22,446,668	$46.7M
7	DAFNA Capital Management LLC	0.79%	2,000,000	$4.2M
8	Tpg GP A, LLC	0.78%	18,716,306	$38.9M
9	Harold Davidson & Associates Inc.	0.25%	281,522	$586K
10	Boxer Capital Management, LLC	0.23%	1,500,000	$3.1M
11	EntryPoint Capital, LLC	0.15%	92,752	$216K
12	Ghisallo Capital Management LLC	0.12%	3,000,000	$6.2M
13	Rangeley Capital, LLC	0.12%	61,500	$128K
14	CFG Wealth Management Services, Inc.	0.11%	40,000	$122K
15	Virtus Investment Advisers, LLC	0.08%	172,209	$358K
16	Rtw Investments, LP	0.06%	3,250,000	$6.8M
17	Headlands Technologies LLC	0.05%	205,453	$427K
18	Hennion & Walsh Asset Management, Inc.	0.04%	722,928	$1.5M
19	Candriam S.C.A.	0.04%	4,336,296	$9.0M
20	Woodline Partners LP	0.03%	4,500,624	$9.4M
21	Raiffeisen Bank International AG	0.03%	1,100,000	$2.4M
22	Xcelsior Advisor Partners LLC	0.03%	95,991	$200K
23	Walleye Capital LLC	0.02%	3,268,012	$6.8M
24	Navalign, LLC	0.02%	49,398	$103K
25	R Squared Ltd	0.02%	20,249	$42K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Allogene Therapeutics Inc (ALLO)

What does the Smart Money Trend signal show for ALLO?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added ALLO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ALLO?

More buyers than sellers — 69% buying: Last quarter: 131 funds were net buyers (51 opened a brand new position + 80 added to an existing one). Only 58 were sellers (43 trimmed + 15 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for ALLO holders?

Elite ownership — 42% AUM from top-100 funds: 45 of 204 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in ALLO. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ALLO?

52% of holders stayed for 2+ years: 107 out of 204 hedge funds have held ALLO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Allogene Therapeutics Inc (ALLO)

Smart Money Signals — ALLO

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Steady growth — +20% more funds vs a year ago

More buyers than sellers — 69% buying

More new buyers each quarter (+21 vs last Q)

52% of holders stayed for 2+ years

Value +95% but shares only +14% — price-driven

Acceleration phase — new buyers rushing in

Veteran-anchored — 61% veterans vs 25% newcomers

Elite ownership — 42% AUM from top-100 funds

Institutional Sentiment Summary — ALLO

Hedge Fund Ownership: ALLO

Market Analysis: ALLO

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ALLO

Hedge Fund Positioning: ALLO

Statistics: ALLO

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Allogene Therapeutics Inc (ALLO)

Welcome to 13Foresight!